Feedback Stories
Acknowlegements
Symptoms
Have I got it?
Who is affected?
What can I do?
The Blues
Bipolar Disorder
Postpartum Psychosis
Anxiety
Alcohol
Cannabis
GAD
PTSD
Panic Disorder
Phobias
OCD
Social Phobia
Risks/treatments
Risks
Self-help
Anxiety
Depression
Bipolar Disorder
Alcohol and Drugs
Future
Attachment
Baby States
Baby Cues
Baby worries
Feeling angry
Childcare
Crying
Sleeping
Feeding
Routine
Effects on Men
Offering Support
Stories
Support
Grandparents
Siblings
Queer families
Rural Isolation
Maori
Pakeha/European
Pasifika
Asian
Migrant & Refuges
Talking Treatments
Selfcare
Selfcare for Anxiety
Medications
CBT
IPT
Biopsychosocial Rhythms
Pregnancy
Lactation
Neonatal Adaptation Syndrome
CAQ
Antidepressants
Mood Stabilisers
Second Generation Antipsychotics
First Generation Antipsychotics
Benzodiazepines and Hypnotics
Other
Tricyclics
SSRI’s
SNRI’s
Others
Citalopram
Fluoxetine
Paroxetine
Sertraline 2013
Venlafaxine
Reboxetine
Buproprion
Mirtazapine
Carbamazepine
Lithium
Lamotrigine
Sodium Valproate
Topiramate
Olanzapine
Quetiapine
Aripiprazole
Risperidone
Ziprasidone
Clozapine
Modafinil
Methylphenidate
Omega 3 Fish Oil
St Johns Wort
South Island
North Island
Otago & Southland
Nelson & Bays
Canterbury
Timaru
West Coast
North Shore
Northland
Auckland Central
Counties Manukau
Waitemata
Rotorua
Taranaki
Waikato
Palmerston North
Wanganui
Bay of Plenty
Wellington
Mood Disorders
Anxiety Disorders
Parent Infant Relationship
Recreational Drugs
Postnatal Depression
Postpartum Psychosis
Bipolar Disorder
Generalised Anxiety Disorders
Post Traumatic Stress Disorder
Panic Disorder
Obsessive Complusive Disorder
Phobias
Social Phobia
Alcohol
Cannabis
Daily Symptom Chart
Weekly Activity Schedule
Relaxation Exercises
Sleep Hygiene
Problem Solving Strategy
Aripiprazole
Carbamazepine
Citalopram and Escitalopram
Clozapine
Fluoxetine
Lamotrigine
Lithium
Mirtazapine
Modafinil
Olanzapine
Paroxetine
Quetiapine
Risperidone
Sodium Valproate
Topiramate
Tricyclic Antidepressants
Venlafaxine
Ziprasidone
Zopliclone




















home >> medical info >> recreational drugs >> Cannabis

Cannabis abuse and dependence

These figures are taken from the 2006 New Zealand Mental Health Survey (Te Hinengaro)

  • The prevalence of Cannabis Abuse in New Zealand is 0.9% overall, but 3.2% 16-24yr age group
  • The prevalence of Cannabis Dependence 0.5% overall, but 1.5% in the16-24yr age group
  • Any Substance Disorder 9.6% in 16-24 age group i.e. almost 1in 10 of the 16-24 age group. It is also worth noting that it has been shown that the instruments used in this study may quite likely under report substance disorder.
  • These figures are not gender selected. Although women usually have a lower prevalence use in pregnancy and around a baby is particularly concerning. Furthermore, they and their babies may be greatly affected by a partner’s substance disorder.

For more information

See information for women on Cannabis.

Read previous Return to intro
Alcohol Medical Info


Home | About us | Baby | Books & Links | Contact Us | Culture | Fact Sheets | Family/Whanau | Fathers | Glossary | Medical Info | Medications | Post Natal Depression | Pregnancy | Q&A | Related Conditions | Stories | Support | Treatments

Powerd by SmartAlec